Loading...
•
Mar 31, 2023
Pacific Biosciences Q1 2023 Earnings Report
Pacific Biosciences reported mixed Q1 2023 results, exceeding revenue expectations but falling short on earnings per share.
Key Takeaways
Pacific Biosciences' Q1 2023 revenue reached $38.7 million, surpassing expectations, but the company experienced a net loss, resulting in negative EPS. Instrument revenue grew, while consumables revenue declined slightly. The company highlighted progress in its product development and market expansion efforts.
Revenue reached $38.7 million, exceeding expectations.
Instrument revenue increased year-over-year.
Consumables revenue experienced a slight decline compared to the previous year.
The company is making progress on product development and market expansion.
Revenue by Segment
Forward Guidance
PacBio anticipates revenue between $165 million and $175 million for the full year 2023.
Positive Outlook
- Revenue between $165 million and $175 million for the full year 2023.
- Continued growth in instrument revenue expected.
- Anticipated increase in consumables revenue as installed base expands.
- Focus on expanding market reach and customer base.
- Advancements in product development to drive future growth.
Challenges Ahead
- Uncertainties in the macroeconomic environment could impact sales.
- Potential delays in product development timelines.
- Increased competition in the long-read sequencing market.
- Fluctuations in currency exchange rates may affect international revenue.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...